| (Values in U.S. Thousands) | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2021 |
| Sales | 92,397 | 50,737 | 21,234 | 24,194 | 0 |
| Sales Growth | +82.11% | +138.94% | -12.23% | unch | unch |
| Net Income | 16,715 | 2,992 | -8,145 | -10,343 | 0 |
| Net Income Growth | +458.66% | +136.73% | +21.25% | unch | unch |
Sourcebio International Plc (SBI.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
SourceBio International PLC is an international provider of integrated laboratory services and products to clients in the healthcare, clinical, life science research, and biopharma industries, with a focus on improving patient diagnosis, management and care. Its revenues are derived from four core businesses areas namely Healthcare Diagnostics; Genomics; Stability Storage; and Infectious Disease Testing. The offerings will provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future.
Fiscal Year End Date: 12/31